scholarly journals Duodenal Chromogranin A Cell Density as a Biomarker for the Diagnosis of Irritable Bowel Syndrome

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Magdy El-Salhy ◽  
Odd Helge Gilja ◽  
Doris Gundersen ◽  
Jan Gunnar Hatlebakk ◽  
Trygve Hausken
Keyword(s):  
Irritable Bowel Syndrome ◽  
Cell Density ◽  
Chromogranin A ◽  
Control Group ◽  
Common Marker ◽  
Sophisticated Equipment ◽  
A Cell ◽  
Gastrointestinal Complaints ◽  
Abc Method ◽  
Irritable Bowel

Background and Aim. Chromogranin A (CgA) is a common marker for endocrine cells. The density of duodenal CgA cells is reduced in patients with irritable bowel syndrome (IBS).Methods. The present study was undertaken to evaluate the density of duodenal CgA as a biomarker for the diagnosis of IBS. Two hundred and three patients with IBS were recruited (180 females and 23 males; mean age, 36 years; range, 18–66 years). The control group comprised 86 healthy subjects without gastrointestinal complaints (77 females and 9 males; mean age, 38 years; range, 18–67 years). Biopsy samples were taken from the duodenum during gastroscopy. Sections from these biopsy samples were immunostained for CgA using the avidin-biotin complex (ABC) method. CgA cell density was quantified by computerized image analysis.Results. The CgA cell density was lower in IBS-total and in all of the IBS subgroups than in the controls. The sensitivity and specificity for a cutoff of <200 cells/mm2were 86% and 95%, respectively.Conclusion. The duodenal CgA cell density seems to be a good biomarker for the diagnosis of IBS. It is an inexpensive, simple, and easy-to-use method that does not require sophisticated equipment or considerable experience.

scholarly journals Increased Chromogranin A Cell Density in the Large Intestine of Patients with Irritable Bowel Syndrome after Receiving Dietary Guidance

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Tarek Mazzawi ◽  
Doris Gundersen ◽  
Trygve Hausken ◽  
Magdy El-Salhy
Keyword(s):  
Irritable Bowel Syndrome ◽  
Cell Density ◽  
Large Intestine ◽  
Chromogranin A ◽  
Endocrine Cells ◽  
Common Marker ◽  
Before And After ◽  
A Cell ◽  
Colon And Rectum ◽  
Irritable Bowel

The large intestine contains five types of endocrine cells that regulate its functions by sensing its luminal contents and releasing specific hormones. Chromogranin A (CgA) is a common marker for the gastrointestinal endocrine cells, and it is abnormal in irritable bowel syndrome (IBS) patients. Most IBS patients relate their symptoms to certain food elements. The present study investigated the effect of dietary guidance on the total endocrine cells of the large intestine as detected by CgA in 13 IBS patients. Thirteen control subjects were also included. Each patient received three sessions of dietary guidance. Colonoscopies were performed on controls and patients (at baseline and at 3–9 months after receiving guidance). Biopsy samples from the colon and rectum were immunostained for CgA and quantified by computerized image analysis. The densities of CgA cells in the total colon (mean ± SEM) among the controls and the IBS patients before and after receiving dietary guidance were83.3±10.1,38.6±3.7, and64.7±4.2cells/mm2, respectively (P=0.0004), and were unchanged in the rectum. In conclusion, the increase in CgA cell density after receiving dietary guidance may reflect a change in the densities of the large intestinal endocrine cells causing an improvement in the IBS symptoms.

scholarly journals Chromogranin A cell density in the rectum of patients with irritable bowel syndrome

2012 ◽  
Vol 6 (6) ◽  
pp. 1223-1225 ◽  
Author(s):  
M. EL-SALHY ◽  
T. MAZZAWI ◽  
D. GUNDERSEN ◽  
T. HAUSKEN
Keyword(s):  
Irritable Bowel Syndrome ◽  
Cell Density ◽  
Chromogranin A ◽  
A Cell ◽  
Irritable Bowel

scholarly journals Increased gastric chromogranin A cell density following changes to diets of patients with irritable bowel syndrome

2014 ◽  
Vol 10 (5) ◽  
pp. 2322-2326 ◽  
Author(s):  
TAREK MAZZAWI ◽  
DORIS GUNDERSEN ◽  
TRYGVE HAUSKEN ◽  
MAGDY EL-SALHY
Keyword(s):  
Irritable Bowel Syndrome ◽  
Cell Density ◽  
Chromogranin A ◽  
A Cell ◽  
Irritable Bowel

scholarly journals Chromogranin A cell density in the large intestine of Asian and European patients with irritable bowel syndrome

2017 ◽  
Vol 52 (6-7) ◽  
pp. 691-697 ◽  
Author(s):  
Magdy El-Salhy ◽  
Tanisa Patcharatrakul ◽  
Jan Gunnar Hatlebakk ◽  
Trygve Hausken ◽  
Odd Helge Gilja ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Cell Density ◽  
Large Intestine ◽  
Chromogranin A ◽  
A Cell ◽  
Irritable Bowel

Difference of Chromogranin a Cell Density in the Large Intestine Between Asian and European Patients with Irritable Bowel Syndrome (IBS)

2017 ◽  
Vol 152 (5) ◽  
pp. S728
Author(s):  
Tanisa Patcharatrakul ◽  
Magdy El-Salhy ◽  
Jan Gunnar Hatlebakk ◽  
Trygve Hausken ◽  
Odd Helge Gilja ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Cell Density ◽  
Large Intestine ◽  
Chromogranin A ◽  
A Cell ◽  
Irritable Bowel

scholarly journals Reduced chromogranin A cell density in the ileum of patients with irritable bowel syndrome

2013 ◽  
Vol 7 (4) ◽  
pp. 1241-1244 ◽  
Author(s):  
MAGDY EL-SALHY ◽  
INGVILD HAUKAAS WENDELBO ◽  
DORIS GUNDERSEN
Keyword(s):  
Irritable Bowel Syndrome ◽  
Cell Density ◽  
Chromogranin A ◽  
A Cell ◽  
Irritable Bowel

scholarly journals Blastocystis sp. Carriage and Irritable Bowel Syndrome: Is the Association Already Established?

Biology ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 340
Author(s):  
Fernando Salvador ◽  
Beatriz Lobo ◽  
Lidia Goterris ◽  
Carmen Alonso-Cotoner ◽  
Javier Santos ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Microscopic Examination ◽  
Parasitic Infection ◽  
Diagnostic Technique ◽  
Control Group ◽  
Cross Sectional ◽  
Significant Difference ◽  
Blastocystis Sp ◽  
Irritable Bowel ◽  
Asymptomatic Subjects

Background: The aim of the present study is to describe the occurrence of Blastocystis sp. detection among asymptomatic subjects and patients with irritable bowel syndrome in order to evaluate the potential association between irritable bowel syndrome and the parasitic infection. Methods: Cross-sectional study where adult patients with irritable bowel syndrome diagnosed according to Rome IV criteria were included. A control group was formed by asymptomatic subjects older than 18 years. Exclusion criteria were: immunosuppressive condition or having received any drug with demonstrated activity against Blastocystis sp. within the last 6 months before study inclusion. Epidemiological and clinical information was collected from all included participants. Two stool samples were obtained from all participants: one sample for microscopic examination and one sample for Blastocystis sp. PCR detection. Blastocystis sp. infection was defined by the positivity of any of the diagnostic techniques. Results: Seventy-two participants were included (36 asymptomatic subjects and 36 patients with irritable bowel syndrome). Thirty-five (48.6%) were men, and median age of participants was 34 (IQR 29–49) years. The overall rate of Blastocystis sp. carriage was 27.8% (20/72). The prevalence assessed through microscopic examination was 22.2% (16/72), while the prevalence measured by PCR was 15.3% (11/72). When comparing the presence of Blastocystis sp. between asymptomatic subjects and IBS patients, we did not find any statistically significant difference (36.1% vs. 19.4% respectively, p = 0.114). Conclusions: regarding the occurrence of Blastocystis sp., no differences were found between asymptomatic participants and patients with irritable bowel disease irrespective of the diagnostic technique performed.

scholarly journals Digestive symptoms in daily life of chronic adrenal insufficiency patients are similar to irritable bowel syndrome symptoms

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
L. Quénéhervé ◽  
D. Drui ◽  
J. Blin ◽  
M. Péré ◽  
E. Coron ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Irritable Bowel Syndrome ◽  
Adrenal Insufficiency ◽  
Gastrointestinal Symptoms ◽  
Control Group ◽  
Non Profit ◽  
Acute Adrenal Insufficiency ◽  
Irritable Bowel ◽  
Rome Iv

AbstractGastrointestinal symptoms are frequent in acute adrenal insufficiency. Although digestive symptoms can significantly reduce quality of life, they are rarely described in patients with treated chronic adrenal insufficiency (CAI). We aimed to characterize digestive symptoms in CAI patients. We used the section pertaining functional bowel disorders of the Rome IV questionnaire. A questionnaire was published on the website of the non-profit patient association “Adrenals” (NPPA of CAI patients) for five months. Information on demographics, characteristics of adrenal insufficiency, digestive symptoms and quality of life was collected. The relatives of CAI patients served as a control group. We analyzed responses of 33 control subjects and 119 patients (68 primary adrenal insufficiency (PAI), 30 secondary adrenal insufficiency (SAI) and 21 congenital adrenal hyperplasia (CAH)). Abdominal pain at least once a week over the past 3 months was reported by 40%, 47% and 33% of patients with PAI, SAI and CAH respectively versus 15% for the controls (p = 0.01). Symptoms were consistent with the Rome IV criteria for irritable bowel syndrome in 27%, 33% and 33% of patients respectively versus 6% for the controls (p < 0.0001). Quality of life was described as poor or very poor in 35%, 57% and 24% of patients respectively versus 5% for the controls (p < 0.0001). In conclusion, digestive symptoms are frequent and incapacitating in CAI patients and similar to symptoms of irritable bowel syndrome in 30% of CAI patients. Assessment and management of digestive symptoms should be considered a priority for physicians treating patients with CAI.

scholarly journals Integrative analysis of the gut microbiome and metabolome in a rat model with stress induced irritable bowel syndrome

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yue Hu ◽  
Fang Chen ◽  
Haiyong Ye ◽  
Bin Lu
Keyword(s):  
Irritable Bowel Syndrome ◽  
Gut Microbiota ◽  
Rat Model ◽  
Gut Microbiome ◽  
16S Rrna Gene Sequencing ◽  
Metabolic Phenotype ◽  
Control Group ◽  
Rrna Gene ◽  
Microbial Dysbiosis ◽  
Irritable Bowel

AbstractStress is one of the major causes of irritable bowel syndrome (IBS), which is well-known for perturbing the microbiome and exacerbating IBS-associated symptoms. However, changes in the gut microbiome and metabolome in response to colorectal distention (CRD), combined with restraint stress (RS) administration, remains unclear. In this study, CRD and RS stress were used to construct an IBS rat model. The 16S rRNA gene sequencing was used to characterize the microbiota in ileocecal contents. UHPLC-QTOF-MS/MS assay was used to characterize the metabolome of gut microbiota. As a result, significant gut microbial dysbiosis was observed in stress-induced IBS rats, with the obvious enrichment of three and depletion of 11 bacterial taxa in IBS rats, when compared with those in the control group (q < 0.05). Meanwhile, distinct changes in the fecal metabolic phenotype of stress-induced IBS rats were also found, including five increased and 19 decreased metabolites. Furthermore, phenylalanine, tyrosine and tryptophan biosynthesis were the main metabolic pathways induced by IBS stress. Moreover, the altered gut microbiota had a strong correlation with the changes in metabolism of stress-induced IBS rats. Prevotella bacteria are correlated with the metabolism of 1-Naphthol and Arg.Thr. In conclusion, the gut microbiome, metabolome and their interaction were altered. This may be critical for the development of stress-induced IBS.

scholarly journals Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report

2020 ◽  
Vol 9 (8) ◽  
pp. 2353
Author(s):  
Gian Paolo Caviglia ◽  
Alessandra Tucci ◽  
Rinaldo Pellicano ◽  
Sharmila Fagoonee ◽  
Chiara Rosso ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Clinical Response ◽  
Bifidobacterium Longum ◽  
Gastrointestinal Symptoms ◽  
Intestinal Barrier ◽  
Response To Therapy ◽  
Intestinal Barrier Function ◽  
Control Group ◽  
Placebo Control ◽  
Irritable Bowel

Bifidobacterium longum (B. longum) ES1 is a probiotic strain capable of modulating microbiome composition, anti-inflammatory activity and intestinal barrier function. We investigated the use of B. Longum ES1 in the treatment of patients with diarrhoea-predominant irritable bowel syndrome (IBS-D). Sixteen patients were treated for 8 or 12 weeks with B. Longum ES1 (1 × 109 CFU/day). Serum zonulin and cytokines were measured at baseline (T0) and at the end of therapy (T1). Clinical response to therapy was assessed by IBS Severity Scoring System. Interleukin (IL)-6, IL-8, IL-12p70 and tumor necrosis factor (TNF) α levels decreased from T0 to T1, irrespective of treatment duration (p < 0.05), while zonulin levels diminished only in patients treated for 12 weeks (p = 0.036). Clinical response was observed in 5/16 patients (31%): 4/8 (50%) treated for 12 weeks and 1/8 (13%) treated for 8 weeks. Abdominal pain improved only in patients treated for 12 weeks (5/8 vs. 0/8, p = 0.025), while stool consistency improved regardless of therapy duration (p < 0.001). In conclusion, the results of this pilot study showed, in IBS-D patients treated for 12 weeks with B. longum ES1, a reduction in the levels of pro-inflammatory cytokines, and intestinal permeability as well as an improvement in gastrointestinal symptoms, but further studies including a placebo-control group are necessary to prove a causal link.

Sign in / Sign up

Export Citation Format

Share Document